NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 110 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $45,353 | -3.5% | 17,511 | +52.1% | 0.00% | – |
| Q1 2023 | $46,985 | -18.7% | 11,516 | 0.0% | 0.00% | – |
| Q4 2022 | $57,810 | -44.9% | 11,516 | +43.2% | 0.00% | -100.0% |
| Q3 2022 | $105,000 | +1.9% | 8,040 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $103,000 | -16.3% | 8,040 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $123,000 | -30.5% | 8,040 | -19.3% | 0.00% | 0.0% |
| Q4 2021 | $177,000 | +311.6% | 9,968 | +383.6% | 0.00% | – |
| Q3 2021 | $43,000 | +4.9% | 2,061 | +0.1% | 0.00% | – |
| Q2 2021 | $41,000 | -28.1% | 2,058 | +4.3% | 0.00% | – |
| Q1 2021 | $57,000 | – | 1,973 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |